Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
2.
Int J Med Microbiol ; 308(3): 364-377, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29490877

ABSTRACT

Infection with the emerging pathogen Clostridioides (Clostridium) difficile might lead to colonization of the gastrointestinal tract of humans and mammals eventually resulting in antibiotic-associated diarrhea, which can be mild to possibly life-threatening. Recurrences after antibiotic treatment have been described in 15-30% of the cases and are either caused by the original (relapse) or by new strains (reinfection). In this study, we describe a patient with ongoing recurrent C. difficile infections over 13 months. During this time, ten C. difficile strains of six different ribotypes could be isolated that were further characterized by phenotypic and genomic analyses including motility and sporulation assays, growth fitness and antibiotic susceptibility as well as whole-genome sequencing. PCR ribotyping of the isolates confirmed that the recurrences were a mixture of relapses and reinfections. One recurrence was due to a mixed infection with three different strains of two different ribotypes. Furthermore, genomes were sequenced and multi-locus sequence typing (MLST) was carried out, which identified the strains as members of sequence types (STs) 10, 11, 14 and 76. Comparison of the genomes of isolates of the same ST originating from recurrent CDI (relapses) indicated little within-patient microevolution and some concurrent within-patient diversity of closely related strains. Isolates of ribotype 126 that are binary toxin positive differed from other ribotypes in various phenotypic aspects including motility, sporulation behavior and cell morphology. Ribotype 126 is genetically related to ribotype 078 that has been associated with increased virulence. Isolates of the ribotype 126 exhibited elongated cells and a chaining phenotype, which was confirmed by membrane staining and scanning electron microscopy. Furthermore, this strain exhibits a sinking behavior in liquid medium in stationary growth phase. Taken together, our observation has proven multiple CDI recurrences that were based on a mixture of relapses and reinfections.


Subject(s)
Clostridioides difficile/classification , Clostridioides difficile/genetics , Clostridium Infections/microbiology , Genetic Variation , Genotype , Phenotype , Aged , Anti-Bacterial Agents/therapeutic use , Clostridioides difficile/drug effects , Clostridioides difficile/isolation & purification , Clostridium Infections/drug therapy , Feces/microbiology , Genome, Bacterial , Humans , Male , Microbial Sensitivity Tests , Multilocus Sequence Typing , Polymerase Chain Reaction , Recurrence , Ribotyping , Whole Genome Sequencing
3.
Gut ; 66(1): 6-30, 2017 01.
Article in English | MEDLINE | ID: mdl-27707777

ABSTRACT

Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Helicobacter pylori , Proton Pump Inhibitors/therapeutic use , Stomach Neoplasms/diagnosis , Amoxicillin/therapeutic use , Bismuth/therapeutic use , Clarithromycin/therapeutic use , Drug Resistance, Bacterial , Drug Therapy, Combination , Dyspepsia/microbiology , Early Detection of Cancer , Evidence-Based Medicine , Fluoroquinolones/therapeutic use , Gastritis/microbiology , Gastrointestinal Microbiome , Gastroscopy , Helicobacter Infections/complications , Helicobacter Infections/prevention & control , Humans , Microbial Sensitivity Tests , Nitroimidazoles/therapeutic use , Practice Guidelines as Topic , Risk Factors , Stomach/microbiology , Stomach Neoplasms/microbiology
5.
Med Mycol ; 54(8): 781-6, 2016 Nov 01.
Article in English | MEDLINE | ID: mdl-27364649

ABSTRACT

The knowledge on prevalence rates of yeasts and moulds in patients with cystic fibrosis (CF) in Germany is scarce. The aim of this report is to give an overview of the diversity and epidemiology of fungal species in CF patients. Over a 5-year period, all fungal isolates cultured from microbiological specimen from CF patients were recorded. Beside standard bacteriological culture media two fungal media were used for cultivation. Species were identified by microscopy, biochemical profiling, MALDI-TOF analysis or DNA sequencing methods. In sum, 25,975 clinical samples from CF patients were analyzed. About 75% of CF patients were colonized by yeasts, mainly Candida albicans (38%) and Candida dubliniensis (12%). In 35% of the patients Aspergillus spp. (Aspergillus fumigatus: 29%) were detected, followed by Exophiala dermatitidis and Scedosporium/Lomentospora complex isolates (4% each). Data for other fungal species are shown. Over a 5-year period, the epidemiology of fungal species detected in CF patients was relatively constant. Clinical microbiology laboratories should carefully monitor samples from CF patients for newly occurring fungal pathogens.


Subject(s)
Cystic Fibrosis/complications , Fungi/classification , Fungi/isolation & purification , Lung Diseases, Fungal/epidemiology , Lung Diseases, Fungal/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Germany/epidemiology , Humans , Infant , Infant, Newborn , Male , Microbiological Techniques , Microscopy , Middle Aged , Mycological Typing Techniques , Prevalence , Sequence Analysis, DNA , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Young Adult
6.
Z Gastroenterol ; 54(4): 1, 2016 Apr.
Article in German | MEDLINE | ID: mdl-27168132

ABSTRACT

In the line "bismuth-containing quadruple therapy" of Table 7 (p 342), in the column "dosage" incorrectly at the three antibiotics respectively 1-1-1-1. The correct is: 3-3-3-3.

7.
Mucosal Immunol ; 9(2): 444-57, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26307665

ABSTRACT

Foxp3 (forkhead box P3 transcription factor)-expressing regulatory T cells (Tregs) are essential for immunological tolerance, best illustrated by uncontrolled effector T-cell responses and autoimmunity upon loss of Foxp3 expression. Tregs can adopt specific effector phenotypes upon activation, reflecting the diversity of functional demands in the different tissues of the body. Here, we report that Foxp3(+)CD4(+) T cells coexpressing retinoic acid-related orphan receptor-γt (RORγt), the master transcription factor for T helper type 17 (Th17) cells, represent a stable effector Treg lineage. Transcriptomic and epigenetic profiling revealed that Foxp3(+)RORγt(+) T cells display signatures of both Tregs and Th17 cells, although the degree of similarity was higher to Foxp3(+)RORγt(-) Tregs than to Foxp3(-)RORγt(+) T cells. Importantly, Foxp3(+)RORγt(+) T cells were significantly demethylated at Treg-specific epigenetic signature genes such as Foxp3, Ctla-4, Gitr, Eos, and Helios, suggesting that these cells have a stable regulatory rather than inflammatory function. Indeed, adoptive transfer of Foxp3(+)RORγt(+) T cells in the T-cell transfer colitis model confirmed their Treg function and lineage stability in vivo, and revealed an enhanced suppressive capacity as compared with Foxp3(+)RORγt(-) Tregs. Thus, our data suggest that RORγt expression in Tregs contributes to an optimal suppressive capacity during gut-specific immune responses, rendering Foxp3(+)RORγt(+) T cells as an important effector Treg subset in the intestinal system.


Subject(s)
Colitis/immunology , Forkhead Transcription Factors/immunology , Immunity, Mucosal/drug effects , Nuclear Receptor Subfamily 1, Group F, Member 3/immunology , T-Lymphocytes, Regulatory/immunology , Adoptive Transfer , Animals , CTLA-4 Antigen/genetics , CTLA-4 Antigen/immunology , Carrier Proteins/genetics , Carrier Proteins/immunology , Cell Lineage , Colitis/genetics , Colitis/pathology , Colon/immunology , Colon/pathology , DNA-Binding Proteins/genetics , DNA-Binding Proteins/immunology , Epigenesis, Genetic/immunology , Female , Forkhead Transcription Factors/genetics , Glucocorticoid-Induced TNFR-Related Protein/genetics , Glucocorticoid-Induced TNFR-Related Protein/immunology , Inflammation , Lymphocyte Activation , Mice , Mice, Inbred C57BL , Mice, Knockout , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/immunology , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Signal Transduction , T-Lymphocytes, Regulatory/pathology , T-Lymphocytes, Regulatory/transplantation , Transcription Factors/genetics , Transcription Factors/immunology
9.
J Cyst Fibros ; 14(2): 237-41, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25595044

ABSTRACT

OBJECTIVE: Detection of hyphomycetes of the Scedosporium apiospermum complex and Lomentospora prolificans (Sac-Lp) is not yet standardized. Prevalence rates in patients with cystic fibrosis (CF) and the resistance pattern of these pathogens in Germany are unknown. METHODS: In a one-year prospective study 11 laboratories used a selective medium for isolation of Sac-Lp, examining >11,600 respiratory samples from 2346 patients with CF. Isolates were identified by molecular methods and tested for susceptibility to antifungal drugs. RESULTS: The prevalence of Sac-Lp in patients with CF in Germany varied from 0.0 to 10.5% (mean: 3.1%) among the clinical centres. The benefit of the selective medium SceSel(+) compared to standard media for fungi was documented for >5000 samples. High antifungal resistance was detected in the S. apiospermum complex, and the multiresistance of L. prolificans was confirmed. CONCLUSION: Microbiology laboratories should be aware of these resistant species in patients with CF and consider using a selective medium.


Subject(s)
Antifungal Agents/pharmacology , Culture Media/pharmacology , Cystic Fibrosis , Mycoses , Scedosporium , Adult , Cystic Fibrosis/complications , Cystic Fibrosis/epidemiology , Cystic Fibrosis/microbiology , Drug Resistance, Fungal , Female , Germany/epidemiology , Humans , Male , Microbial Sensitivity Tests/methods , Mycoses/diagnosis , Mycoses/epidemiology , Mycoses/etiology , Mycoses/microbiology , Prevalence , Prospective Studies , Scedosporium/classification , Scedosporium/drug effects , Scedosporium/isolation & purification
10.
Forensic Sci Int ; 226(1-3): 266-72, 2013 Mar 10.
Article in English | MEDLINE | ID: mdl-23434379

ABSTRACT

Procalcitonin is regarded as a valuable marker for sepsis in living persons and even in post-mortem investigations. At the Institute of Legal Medicine, 25 autopsy cases with suspected bacterial infectious diseases or sepsis were examined using the semi-quantitative PCT-Q(®)-test (B.R.A.H.M.S., Germany) in 2010 and 2011. As controls, 75 cadavers were used for which there was no suspicion of a bacterial infectious disease or sepsis. Femoral blood was cultured from the cases and from controls, and samples from the brain, heart, lungs, liver, spleen and kidneys were examined histologically for findings seen in sepsis. Twelve cases in the sepsis/infectious disease group (48%) were classifiable as sepsis following synopsis of PCT levels, autopsy results, and histopathological and microbiological findings. This study shows that the semi-quantitative PCT-Q(®)-test is a useful supplementary marker in routine autopsy investigations, capable of classifying death as due to sepsis.


Subject(s)
Calcitonin/blood , Protein Precursors/blood , Sepsis/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Brain/pathology , Calcitonin Gene-Related Peptide , Case-Control Studies , Female , Forensic Pathology , Granulocytes/pathology , Humans , Kidney/pathology , Leukocytes/pathology , Liver/pathology , Lung/pathology , Male , Middle Aged , Myocardium/pathology , Prospective Studies , Spleen/pathology , Young Adult
12.
Zentralbl Chir ; 136(1): 74-8, 2011 Feb.
Article in German | MEDLINE | ID: mdl-21337294

ABSTRACT

BACKGROUND: So-called polyphasic nosocomial outbreaks describe a situation in which additional infections occur after a certain case-free interval - despite the detection of the outbreak's source. This article summarises the results of a systematic search of the medical literature on polyphasic outbreaks. MATERIALS AND METHODS: For this purpose, the Outbreak Worldwide-Database, PubMed and reference lists of relevant articles were screened. RESULTS: A total of 124 polyphasic outbreaks (median duration of 50 weeks) was included in the analysis and then compared to 2089 monophasic nosocomial outbreaks. Surgical departments were significantly more often involved in polyphasic outbreaks than they were in monophasic events (33.9 % vs. 24.5 %; p < 0.05). Hepatitis B virus outbreaks were significantly more often seen as poly-phasic events. Either there had been more than one source initially, or a new source developed during the first phase of the outbreak and led to additional cases thereafter. CONCLUSIONS: Up to now, only little is known about polyphasic nosocomial outbreaks. Thus, there is a further need to close this gap of information in the future. Personnel on the ward as well as -infection control staff should always consider the possibility of the existence of more than one -source when investigating a nosocomial outbreak.


Subject(s)
Cross Infection/epidemiology , Disease Outbreaks/statistics & numerical data , Surgery Department, Hospital/statistics & numerical data , Bacterial Infections/epidemiology , Bacterial Infections/prevention & control , Bacterial Infections/transmission , Carrier State , Contact Tracing , Cross Infection/prevention & control , Cross Infection/transmission , Cross-Cultural Comparison , Cross-Sectional Studies , Disease Outbreaks/prevention & control , Health Surveys , Hepatitis B/epidemiology , Humans , Mycoses/epidemiology , Mycoses/prevention & control , Mycoses/transmission , Quality Assurance, Health Care , Recurrence , Risk Management , Virus Diseases/epidemiology , Virus Diseases/prevention & control , Virus Diseases/transmission
13.
Z Gastroenterol ; 47(1): 68-102, 2009 Jan.
Article in German | MEDLINE | ID: mdl-19156594

ABSTRACT

This guideline updates a prior concensus recommendation of the German Society for Digestive and Metabolic Diseases (DGVS) from 1996. It was developed by an interdisciplinary cooperation with representatives of the German Society for Microbiology, the Society for Pediatric Gastroenterology and Nutrition (GPGE) and the German Society for Rheumatology. The guideline is methodologically based on recommendations of the Association of the Scientific Medical Societies in Germany (AWMF) for providing a systematic evidence-based consensus guideline of S 3 level and has also implemented grading criteria according to GRADE (Grading of Recommendations Assessment, Development and Evaluation). Clinical applicability of study results as well as specifics for Germany in terms of epidemiology, antibiotic resistance status, diagnostics and therapy were taken into account.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Evidence-Based Medicine , Helicobacter Infections/drug therapy , Helicobacter pylori , Peptic Ulcer/drug therapy , Adolescent , Adult , Child , Cross-Sectional Studies , Drug Therapy, Combination , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Gastroscopy , Helicobacter Infections/diagnosis , Helicobacter Infections/epidemiology , Humans , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell/prevention & control , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, B-Cell, Marginal Zone/prevention & control , Neoplasm Staging , Peptic Ulcer/diagnosis , Peptic Ulcer/epidemiology , Randomized Controlled Trials as Topic , Stomach Neoplasms/pathology , Stomach Neoplasms/prevention & control
14.
Infection ; 36(3): 207-12, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18470477

ABSTRACT

We investigated to which extent bacterial and fungal donor organ contamination (DOC) caused posttransplant nosocomial infections (NI) in solid organ transplant (Tx) recipients. Between January 2002 to December 2003 (lung and heart Tx) and October 2003 to September 2004 (liver Tx), NIs were determined according to modified CDC criteria for NIs for all transplantations performed at Hannover Medical School. Organisms of the same species cultured from donor organs and infected transplantees were genotyped if available. Out of 282 solid organ recipients (140 lung-Tx, 16 heart-lung-Tx, 51 heart-Tx, 75 liver-Tx), 150 recipients (53.2%) received contaminated donor organs. Incidences of NIs were 33.7% in lung, 68.8% in heart-lung, 21.6% in heart, and 28% in liver recipients. In 11 out of 282 transplantees (3.9%, CI (95%) 2.0-6.9%) organisms of NIs and of contamination of the donor organ were of the same species. Even if assuming five missing pairs of organisms as genetically identical, incidences of DOC-related posttransplant infections were only between 1.3% (CI(95%) 0.0; 7.2) in liver-Tx and 18.8% (CI(95%) 4; 45.6) in heart-lung Tx, and DOC related mortality was 0.4% (CI(95%) 0.0;1.9). Despite high DOC rates, posttransplant infections due to DOC were rare under the condition of adequate preoperative antibiotic prophylaxis and aseptic organ retrievement.


Subject(s)
Cross Infection/epidemiology , Cross Infection/microbiology , Heart/microbiology , Liver/microbiology , Lung/microbiology , Organ Transplantation/adverse effects , Tissue Donors , Female , Fungi/isolation & purification , Gram-Negative Bacteria/isolation & purification , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , Gram-Positive Bacteria/isolation & purification , Gram-Positive Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/microbiology , Heart Transplantation/adverse effects , Heart-Lung Transplantation/adverse effects , Humans , Incidence , Liver Transplantation/adverse effects , Lung Transplantation/adverse effects , Male , Middle Aged , Mycoses/epidemiology , Mycoses/microbiology
15.
Hautarzt ; 59(4): 319-22, 2008 Apr.
Article in German | MEDLINE | ID: mdl-17646948

ABSTRACT

We report cases of immunocompetent patients showing multiple abscesses by a Panton-Valentine leukocidin (PVL) positive Staphylococcus aureus. PVL is considered to be an important virulence factor. The most common manifestations by this pathogen are recurrent or multiple abscesses of the skin. Seldom necrotizing pneumonia with high mortality occurs. Even methicillin-resistant PVL positive isolates have been identified in Germany. Only appropriate infection control measures in combination with antimicrobial therapy resulted in successful eradication of this pathogen. Dermatologists should be informed about this specific type of infection and about the appropriate infection control measures.


Subject(s)
Abscess/microbiology , Bacterial Toxins , Exotoxins , Leukocidins , Staphylococcal Skin Infections , Staphylococcus aureus/pathogenicity , Abscess/drug therapy , Abscess/prevention & control , Adolescent , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Child , Drug Resistance, Bacterial , Female , Follow-Up Studies , Humans , Infection Control , Male , Methicillin/pharmacology , Methicillin Resistance , Pneumonia, Staphylococcal/etiology , Recurrence , Retrospective Studies , Staphylococcal Skin Infections/diagnosis , Staphylococcal Skin Infections/drug therapy , Staphylococcal Skin Infections/prevention & control , Staphylococcus aureus/drug effects , Staphylococcus aureus/isolation & purification , Time Factors , Treatment Outcome , Virulence
16.
Rheumatol Int ; 27(11): 1091-3, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17406870

ABSTRACT

We present a 10-year-old girl who had been diagnosed with juvenile idiopathic arthritis 5 years before and who experienced a flare of arthritis affecting one knee while she was off medication for almost 3 years. Seronegative Lyme arthritis had to be diagnosed based on the detection of Borrelia burgdorferi DNA in synovial fluid. No humoral immune response to Borrelia burgdorferi was detectable before, at the time of diagnosis and up to 3 years later.


Subject(s)
Arthritis, Juvenile/diagnosis , Borrelia burgdorferi/genetics , Diagnostic Errors , Knee Joint/microbiology , Lyme Disease , Synovial Fluid/microbiology , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Infectious/genetics , Arthritis, Juvenile/drug therapy , Child , DNA, Bacterial/analysis , Female , Humans , Lyme Disease/blood , Lyme Disease/drug therapy , Lyme Disease/immunology , Polymerase Chain Reaction , Remission Induction
17.
J Oral Rehabil ; 34(5): 377-82, 2007 May.
Article in English | MEDLINE | ID: mdl-17441878

ABSTRACT

Biofilm formation on oral implants can cause inflammation of peri-implant tissues, which endangers the long-term success of osseointegrated implants. It has been reported previously that implants revealing signs of peri-implantitis contain subgingival microbiota similar to those of natural teeth with periodontitis. The purpose of the first part of this study was an atraumatic, quantitative investigation of biofilm formation on oral implant abutments; the objective of the second part was to investigate whether Haemophilus actinomycetemcomitans and Porphyromonas gingivalis were present in the crevicular fluid around oral implants. Biofilm formation on 14 healing abutments, inserted for 14 days in 10 patients, was analysed quantitatively by use of secondary-electron and Rutherford-backscattering-detection methods. A 16S rRNA-based polymerase chain reaction detection method was used to detect the presence of H. actinomycetemcomitans and P. gingivalis in the crevicular fluid. For this investigation, samples of sulcus fluid were collected with sterile paper points at four measurement points per abutment. The difference between biofilm coverage of supragingival surfaces (17.5 +/- 18.3%) and subgingival surfaces (0.8 +/- 1.0%) was statistically significant (P < 0.05). By use of universal primers, bacteria were found in all the samples taken, although the two periodontal pathogens were not found in any of the samples. The absence of periodontal pathogens from the sulcus fluid during initial bacterial colonization, despite massive supragingival biofilm formation, substantiates the assumption that cellular adherence of peri-implant tissue by means of hemidesmosoma, actin filaments and microvilli reduces the risk of formation of anaerobic subgingival pockets.


Subject(s)
Biofilms/growth & development , Dental Implants/microbiology , Adolescent , Adult , Aged , Dental Abutments/microbiology , Female , Gingival Crevicular Fluid/microbiology , Haemophilus/isolation & purification , Humans , Jaw, Edentulous, Partially/microbiology , Male , Middle Aged , Polymerase Chain Reaction/methods , Porphyromonas gingivalis/isolation & purification
18.
J Hosp Infect ; 66(1): 46-51, 2007 May.
Article in English | MEDLINE | ID: mdl-17350720

ABSTRACT

The usefulness and applicability of isolation precautions were questioned for extended-spectrum beta-lactamase (ESBL)-producing strains of Enterobacteriaceae in the endemic setting. We performed a surveillance programme for ESBL-positive organisms and the infection control management of patients colonized or infected with these organisms. Between 1 January 2002 and 31 December 2004, a total of 147 cases of ESBL-producing strains of Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis from 123 patients were noted. The overall incidence of ESBL-producing-strain-positive cases was 0.12/1000 patient-days. The proportion of referred cases was 35% (N=51); 65% of cases (N=96) were acquired in our institution. Infections developed in 57 cases (38.8%), of which 36 (63.3%) were nosocomial. Contact isolation precautions were carried out for 79.6% of the cases, with a median duration of contact isolation precautions for 14 days (range: 0-144). The contact isolation precautions resulted in 2985 isolation days in total, i.e. 995 isolation days per year. Typing by pulsed-field gel electrophoresis showed clonal diversity in 94.2% of the isolates from patients. Seven patient-to-patient transmissions were noted. Only in 10 cases (6.8%) was colonization with ESBL-producing strains cleared. Considering the large number of immunocompromised patients treated in our institution (>1500 bone marrow or solid organ transplantations performed during 2002-2004), we will continue to isolate patients who are colonized or infected with ESBL-producing organisms.


Subject(s)
Cross Infection/prevention & control , Enterobacteriaceae Infections/prevention & control , Infection Control/methods , Patient Isolation/methods , Sentinel Surveillance , beta-Lactamases/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Cross Infection/epidemiology , Enterobacteriaceae/classification , Enterobacteriaceae/enzymology , Enterobacteriaceae/isolation & purification , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae Infections/epidemiology , Female , Germany , Hospitals, University/statistics & numerical data , Humans , Immunocompromised Host , Infant , Infant, Newborn , Male , Middle Aged , beta-Lactam Resistance
19.
Anaesthesist ; 55(7): 778-83, 2006 Jul.
Article in German | MEDLINE | ID: mdl-16570167

ABSTRACT

In Germany, methicillin-resistant S. aureus (MRSA) is increasing continuously. To control the spread of MRSA, active surveillance and admission screening are recommended. In most cases, screening cultures of patients at risk for MRSA will be sufficient. Screening of all patients admitted to an ICU is cost-effective when the incidence of MRSA and nosocomial MRSA infections is high (>2 cases/100 patients and 0.3 MRSA infections/100 patients, respectively): Under these circumstances, a decrease in the incidence of nosocomial MRSA infections of 50% leads to cost-effectiveness at costs of 16 Euro/sample (including subsequent costs). If the incidence of nosocomial MRSA infections decreases by 75%, costs of 24 Euro/sample (including subsequent costs) are cost-effective. If the incidence of MRSA is high, screening by PCR may be cost-effective for patients at high risk for MRSA, especially if they are isolated prophylactically. Recently, PCR methods have been developed which allow the specific identification of MRSA even from nasal swabs.


Subject(s)
Cross Infection/diagnosis , Cross Infection/prevention & control , Methicillin Resistance , Staphylococcal Infections/diagnosis , Staphylococcal Infections/prevention & control , Staphylococcus aureus/drug effects , Cost-Benefit Analysis , Critical Care , Cross Infection/microbiology , Humans , Staphylococcal Infections/microbiology
20.
Scand J Rheumatol ; 34(2): 148-51, 2005.
Article in English | MEDLINE | ID: mdl-16095013

ABSTRACT

A 34-year-old man with chronic inflammatory joint disease and recurrent fever over 6 years was diagnosed as having Still's disease. Treatment with corticosteroids and azathioprine was ineffective. Therefore, infliximab/ methotrexate was started. The patient subsequently developed a wasting disease with rapid weight loss, erythema nodosum, diarrhoea, progressive lymph node enlargement, and a sigmoido-vesical fistula. Histological analysis of several enlarged lymph nodes, the margins of the fistula, and the small bowel established the diagnosis of Whipple's disease (WD). The presence of Tropheryma whipplei (Tw) DNA in the tissues was confirmed by polymerase chain reaction (PCR). Careful re-evaluation of biopsies taken from the ileum and the liver 2 years earlier, which at that time was not judged to be diagnostic for WD, retrospectively showed subtle histological signs of WD and were positive for Tw DNA. In summary, infliximab treatment seems to increase the risk of exacerbation of WD. WD should be carefully ruled out prior to application of tumour necrosis factor-alpha (TNF-alpha) blockade.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Still's Disease, Adult-Onset/complications , Whipple Disease/etiology , Adult , Anti-Bacterial Agents , DNA, Bacterial/analysis , Drug Combinations , Drug Therapy, Combination/therapeutic use , Gram-Positive Bacteria/genetics , Gram-Positive Bacteria/isolation & purification , Gram-Positive Bacteria/ultrastructure , Humans , Ileum/microbiology , Ileum/pathology , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Infliximab , Liver/microbiology , Liver/pathology , Lymph Nodes/pathology , Male , Methotrexate/adverse effects , Polymerase Chain Reaction , Still's Disease, Adult-Onset/drug therapy , Sulfamethizole/therapeutic use , Treatment Outcome , Trimethoprim/therapeutic use , Whipple Disease/drug therapy , Whipple Disease/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...